Departamento de Imagem, Oncologia e Hematologia - Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo - USP, Ribeirão Preto, SP, Brasil.
Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirao Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.
Int Braz J Urol. 2025 Jan-Feb;51(1). doi: 10.1590/S1677-5538.IBJU.2024.0318.
The objective of this study was to evaluate whether morphological (linear measurements) and functional (ADC value) assessments of periprostatic fat can predict the aggressiveness of prostate cancer (PCa) over a 5-year follow-up period.
This retrospective study included patients with histologically proven PCa who underwent 3.0T MRI between July 2016 and June 2018. Clinical and demographic data collected included PSA, PSA density (dPSA), ISUP grade, clinical and pathological staging, and treatment details. MRI-derived parameters were assessed by an experienced radiologist, who measured subcutaneous and periprostatic fat thickness, and calculated ADC values from ROI plots in periprostatic fat. Clinical and MRI parameters were analyzed for associations with biochemical recurrence, systemic metastasis, and PCa-related mortality.
After applying exclusion criteria, 109 patients were included. Using the Cox model, dPSA (p<0.01), systemic disease at diagnosis (p<0.01), and mean ADC (p<0.02) were independent predictors of overall survival (OS). For progression-free survival (PFS), only dPSA (p<0.01) and systemic disease at diagnosis (p<0.01) were significant predictors. In the Poisson Model for systemic recurrence risk, dPSA had a relative risk (RR) of 1.04 (95%CI 1.0-1.07, p=0.03), systemic disease at diagnosis had an RR of 63.3 (95%CI 3.7-86.4, p<0.01), and average ADC had an RR of 3.42 (95%CI 1.52-7.69, p<0.01).
The ADC value of periprostatic fat may serve as an additional tool for PCa risk stratification, correlating with poorer outcomes such as systemic recurrence and overall survival. If validated by external, prospective, multicenter studies, these findings could impact future therapeutic decisions.
本研究旨在评估前列腺周脂肪的形态学(线性测量)和功能(ADC 值)评估是否可以在 5 年随访期间预测前列腺癌(PCa)的侵袭性。
本回顾性研究纳入了 2016 年 7 月至 2018 年 6 月期间经 3.0T MRI 证实为 PCa 的患者。收集的临床和人口统计学数据包括 PSA、PSA 密度(dPSA)、ISUP 分级、临床和病理分期以及治疗细节。由一名经验丰富的放射科医生评估 MRI 衍生参数,该医生测量皮下和前列腺周脂肪的厚度,并从前列腺周脂肪的 ROI 图中计算 ADC 值。分析临床和 MRI 参数与生化复发、全身转移和与 PCa 相关的死亡率之间的关联。
应用排除标准后,纳入 109 例患者。使用 Cox 模型,dPSA(p<0.01)、诊断时全身疾病(p<0.01)和平均 ADC(p<0.02)是总生存(OS)的独立预测因子。对于无进展生存(PFS),只有 dPSA(p<0.01)和诊断时全身疾病(p<0.01)是显著预测因子。在用于系统性复发风险的泊松模型中,dPSA 的相对风险(RR)为 1.04(95%CI 1.0-1.07,p=0.03),诊断时全身疾病的 RR 为 63.3(95%CI 3.7-86.4,p<0.01),平均 ADC 的 RR 为 3.42(95%CI 1.52-7.69,p<0.01)。
前列腺周脂肪的 ADC 值可能成为 PCa 风险分层的附加工具,与全身复发和总体生存等较差结局相关。如果得到外部、前瞻性、多中心研究的验证,这些发现可能会影响未来的治疗决策。